secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-02-08T23:59:59+00:00
Accession:  0000950170-23-002132
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara reports FY2022 net loss $228.3M, CFO transition, Ebvallo EU launch
------------------------------------------------------------------------

- Cash and investments $242.8M as of Dec 31, 2022; runway extended into Q2 2024.
- Net loss $228.3M ($2.24/share) for FY2022 vs $340.1M ($3.63/share) in FY2021.
- CFO Utpal Koppikar resigns effective March 31, 2023; Eric Hyllengren appointed CFO effective April 1, 2023.
- Ebvallo EU launch led by Pierre Fabre to begin Q1 2023; FDA discussions ongoing for tab-cel BLA.
- ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/atra-20230203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer